229
Participants
Start Date
May 29, 2018
Primary Completion Date
January 27, 2025
Study Completion Date
January 27, 2025
Olaparib 300mg tablets
300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Research Site, Kuala Lumpur
Research Site, Putrajaya
Research Site, Ampang
Research Site, Johor Bahru
Research Site, Kuching
Research Site, Beijing
Research Site, Shenyang
Research Site, Harbin
Research Site, Shanghai
Research Site, Shanghai
Research Site, Shanghai
Research Site, Hefei
Research Site, Jinan
Research Site, Tianjin
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Chongqing
Research Site, Chongqing
Research Site, Changsha
Research Site, Wuhan
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Chengdu
Research Site, Xi'an
Lead Sponsor
AstraZeneca
INDUSTRY